Last updated: July 22, 2026
AUGMENTIN ES-600 (amoxicillin/clavulanate potassium) is positioned for pediatric acute bacterial infections requiring oral, weight-based dosing. Financial trajectory depends on (1) pediatric demand durability, (2) share shift versus alternative amoxicillin/clavulanate suspensions and branded pediatric antibiotics, and (3) payer and formulary uptake. Patent and exclusivity do not appear to be primary value drivers for AUGMENTIN ES-600’s long-run revenue, since amoxicillin/clavulanate is broadly generic and the product’s market exposure is driven by switching, contracting, and NDC-level competition.
What is AUGMENTIN ES-600 and what market does it serve?
AUGMENTIN ES-600 is a pediatric formulation of amoxicillin/clavulanate potassium as an oral suspension, targeted at children needing higher dosing regimens (commonly for infections where clinicians prefer amoxicillin/clavulanate coverage versus amoxicillin alone). Like other pediatric beta-lactam oral suspensions, it competes in short-cycle, acute-use prescriptions rather than chronic therapy.
How does the pediatric antibiotic category typically behave financially?
Acute-care antibiotic demand is driven by:
- seasonal URTI and infectious disease incidence
- pediatric visit volume
- guideline adherence and clinician prescribing patterns (eg, otitis media and sinusitis management)
- payer utilization management (prior authorization, step therapy where applicable)
- substitution at the pharmacy counter based on NDC price and availability
Financial trajectory in these categories usually shows:
- modest year-over-year growth only when prescribing behavior shifts toward the category or toward a specific strength/formulation
- margin pressure from multi-source generic supply
- episodic demand spikes tied to respiratory seasons
What are the principal competitive substitutes?
AUGMENTIN ES-600 competes against:
- other amoxicillin/clavulanate pediatric suspensions (different concentrations and dosing volumes)
- amoxicillin/clavulanate generics at the same strength/dosing
- alternative pediatric antibiotics by syndrome and resistance patterns (macrolides, cephalosporins, etc), which can displace use depending on payer rules and clinical preference
How do exclusivity, patent expiration, and generic entry risk shape AUGMENTIN ES-600 revenue?
For older small-molecule antibiotics like amoxicillin/clavulanate, revenue durability is generally constrained more by generic availability than by premium patent protection. The product’s financial exposure is therefore dominated by:
- generic substitution across the relevant NDC/strength
- pharmacy contracting and WAC-to-actual net pricing dynamics
- competition from multiple labeled strengths and dosing instructions that affect dose rounding and caregiver compliance
What is the likely Orange Book status impact?
AUGMENTIN ES-600 is not expected to have the same regulatory exclusivity leverage as newer branded drugs. In practice, the revenue model for pediatric oral antibiotics is exposed to:
- immediate multi-source dynamics after any regulatory exclusivity lapses
- ongoing price compression from generics and private label contracting
What are the “generic entry” scenarios that matter commercially?
Key commercial risk scenarios:
- Increased generic penetration on the exact strength/directions for use, pushing net price down.
- Pharmacy-level switching to lowest-cost equivalent NDCs (even if clinicians prefer the branded product).
- Discontinuations or supply constraints of competing strengths that temporarily benefit or harm specific NDCs.
- Payer formulary tightening that favors fewer covered NDCs in pediatric antibiotic bundles.
When does AUGMENTIN ES-600 lose market share versus generics?
In branded antibiotics, market share typically erodes quickly after generic coverage expands for the same labeled dosing. The longer-tail effect is that:
- once a generic is established and contracted, pharmacy purchasing shifts toward it
- continued switching depends on net price, rebates, and pharmacy inventory turnover
Because AUGMENTIN ES-600 is an older active ingredient class product, the relevant “loss of exclusivity” is less about a single date and more about the cumulative effect of multi-source coverage and contracting over time.
What is the Orange Book listing and how can it affect competitors?
For branded antibiotic suspensions, the decisive factor is whether specific Orange Book-listed patents cover:
- the formulation and manufacturing method
- the dosing regimen or specific strength
- the composition of matter (rare for older assets) or a narrow refinement
Commercially, the existence of Orange Book listings can slow generic “design-around” only if patents are enforceable and still within term. For amoxicillin/clavulanate pediatric suspensions, the category’s maturity usually limits the protective power of remaining branded listings.
What market dynamics drive prescriptions for pediatric amoxicillin/clavulanate?
How does seasonality impact AUGMENTIN ES-600 demand?
Pediatric antibiotic demand tends to rise during:
- fall and winter respiratory virus seasons, increasing otitis media and sinusitis evaluations
- school terms with higher infectious contact rates
AUGMENTIN ES-600 revenue will usually track:
- outpatient pediatric visit volume
- the proportion of infections where clinicians choose amoxicillin/clavulanate over alternatives
How do stewardship and guidelines shift mix?
Stewardship can reduce inappropriate antibiotic prescribing and shift:
- away from broad-spectrum agents for borderline cases
- toward narrower options when clinically appropriate
For amoxicillin/clavulanate, mix can be helped or hurt by:
- guideline emphasis on “watchful waiting” for certain conditions
- resistance patterns that maintain clinician comfort with beta-lactam/beta-lactamase inhibitor therapy
How strong is the patent estate for AUGMENTIN ES-600 and what is the litigation risk?
Given the active ingredient’s long commercial history, litigation and patent estate strength usually plays a reduced role compared with generics and contracting unless there are still-expiring, product-specific patents for this exact pediatric formulation or manufacturing process. Without a confirmed, up-to-date list of specific Orange Book patents and their expiration dates for AUGMENTIN ES-600, patent strength cannot be translated into a defensible financial forecast.
What formulation patents and manufacturing/IP barriers affect supply?
For oral suspension antibiotics, practical barriers are typically:
- process validation and stability data
- acceptable impurity profiles
- bioequivalence and labeled dosing characteristics
- packaging and reconstitution instructions that ensure caregiver usability
In multi-source categories, manufacturing compliance is usually a cost-of-entry issue rather than a long-term moat, leading to margin pressure once supply expands.
What is the FDA and regulatory status of AUGMENTIN ES-600, and how does it affect pricing?
AUGMENTIN ES-600’s regulatory positioning is central to substitution timing:
- If the product is marketed under an NDA with mature labeling, generics may already have multiple approved ANDAs for equivalent strengths.
- Post-approval changes and safety updates can influence which NDCs remain preferred under payer formularies.
From a pricing perspective, when multiple ANDA sponsors exist, net pricing typically compresses faster than it does in single-sponsor branded markets.
Which companies compete with AUGMENTIN ES-600 and how does that change pricing?
AUGMENTIN ES-600 competes within a crowded field of:
- amoxicillin/clavulanate generic manufacturers
- other branded pediatric oral antibiotics in overlapping therapeutic niches
- pharmacy-benefit contracting intermediaries that steer usage based on net price
In competitive pediatric antibiotic markets, pricing is usually driven by:
- the lowest net cost equivalent covered by PBMs
- supply reliability and pharmacist ordering behavior
- rebate structures and formulary tier placement
How does AUGMENTIN ES-600 compare with alternative amoxicillin/clavulanate pediatric products?
The dominant differentiators among pediatric amoxicillin/clavulanate suspensions are:
- strength per 5 mL (or equivalent) and resulting dosing volume
- caregiver dosing complexity (how often the product must be measured and how accurately)
- palatability and perceived tolerability
- coverage and rebate competitiveness by NDC
From a market-share lens, any product that reduces dosing volume and improves caregiver adherence can gain relative share even when price is similar, because adherence and ease of use reduce missed doses and treatment failure.
What revenue trajectory should investors or licensors expect?
For mature, generic-exposed pediatric antibiotic products, revenue trajectory generally follows:
- early peak around launch, followed by steady decline or flat-to-down growth as generics expand
- periodic stabilization from contracting cycles or supply dynamics
- further compression when PBMs narrow covered NDC lists to a few preferred generics
Financial outcomes hinge on:
- net price vs gross sales mix
- changes in covered NDC count and formulary placement
- market share retention by NDC-strength category
- trade terms and rebate structure changes with distributors and PBMs
How much exposure does AUGMENTIN ES-600 have to competitive erosion?
Exposure is high when:
- multiple ANDA equivalents are covered on formulary
- pharmacy switching is unconstrained
- the branded product is not the preferred tier
Exposure is moderate only when:
- specific labeled strength or dosing instructions are uniquely favored
- payer coverage is limited for alternatives
- supply constraints temporarily protect branded share
Given the market maturity of amoxicillin/clavulanate pediatric formulations, the base case is sustained competitive pressure and margin compression over time.
Key takeaways
- AUGMENTIN ES-600 is an acute, pediatric oral antibiotic product where demand is driven by infection incidence, outpatient pediatric visit volume, and seasonal respiratory patterns.
- The financial model is dominated by multi-source competition, payer contracting, and NDC-level generic substitution rather than long-lived exclusivity.
- Revenue trajectory should be expected to be flat-to-declining with margin compression as formulary preference shifts toward lower-cost equivalent generics.
- Market share resilience, if any, comes from dosing convenience and formulary tier placement, not from patent leverage.
FAQs
1) What drives pharmacy-level substitution for pediatric amoxicillin/clavulanate suspensions?
NDC-level net price, formulary tiering by PBMs, supply availability, and the dosing volume/palatability profile that affects caregiver adherence.
2) Do pediatric antibiotic shortages affect AUGMENTIN ES-600 sales?
Yes. Supply constraints of competing strengths or manufacturers can temporarily shift prescriptions, improving branded and contracted preferred-NDC performance.
3) How do PBM formularies typically impact branded antibiotic suspensions?
They usually expand covered generic options over time, push products to lower reimbursement tiers, and steer dispensing toward preferred net-cost NDCs.
4) Is AUGMENTIN ES-600 mainly exposed to generics or also to therapeutic competitors?
Both. It is structurally exposed to generics within amoxicillin/clavulanate, and tactically exposed to alternative pediatric antibiotics depending on guideline adherence and payer rules by infection type.
5) What metric best predicts longer-term revenue for an acute pediatric antibiotic?
Net sales retention by NDC-strength combined with weighted average realized price versus category/generic equivalents, because volume can shift quickly while contracting determines sustainability.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-22).
